HIMS
the council passes — AVOIDHIMS & HERS HEALTH, INC.·Healthcare
Priced for a story the numbers don't yet back.
62/100C
Price at last run$34.26as of Jul 8, 2026
healthcareHigh returns on capitalROIC ~27% — it earns well on the money it puts to work.
Strong gross margins74% gross margin.
GrowingRevenue growing ~59%.
Catalystnone yet
✕Why not
The honest case against — what most tools hideMain riskvaluation stretched
Hype / valuation riskThe price already embeds a lot of optimism; a stumble re-rates it hard.
Demanding valuationTrading at ~67× earnings — little room for error.
Falling knifeDown 48% from its 1-year high — momentum is against it.
What keeps us out
- Paying up here — we'd want a better entry price.
- Growth slowing while the multiple stays rich.
Patience price & distance
as of Jul 8, 2026 runThe patience price is where value discipline would let the council in — deliberately strict: we'd rather miss ten winners than own one loser.
Catalyst
none yet
A catalyst is a plausible reason the gap could close — never a certainty.